WO2023125787A1 - Biomarqueurs pour le traitement du cancer colorectal - Google Patents

Biomarqueurs pour le traitement du cancer colorectal Download PDF

Info

Publication number
WO2023125787A1
WO2023125787A1 PCT/CN2022/143330 CN2022143330W WO2023125787A1 WO 2023125787 A1 WO2023125787 A1 WO 2023125787A1 CN 2022143330 W CN2022143330 W CN 2022143330W WO 2023125787 A1 WO2023125787 A1 WO 2023125787A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
aberrations
individual
drug resistant
drug sensitive
Prior art date
Application number
PCT/CN2022/143330
Other languages
English (en)
Inventor
Pengfei YUAN
Ming Jin
Yongjian Zhang
Hongyan Shen
Ling Yang
Na LIU
Original Assignee
Edigene Therapeutics (Beijing) Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edigene Therapeutics (Beijing) Inc. filed Critical Edigene Therapeutics (Beijing) Inc.
Publication of WO2023125787A1 publication Critical patent/WO2023125787A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des biomarqueurs associés à la sensibilité ou à la résistance du cancer colorectal d'un individu à un traitement avec un inhibiteur de BRAF, ainsi que des méthodes, des kits et des réactifs pour détecter de tels biomarqueurs. L'invention concerne également des méthodes d'évaluation, d'identification, d'évaluation et/ou de traitement d'un individu atteint d'un cancer colorectal.
PCT/CN2022/143330 2021-12-31 2022-12-29 Biomarqueurs pour le traitement du cancer colorectal WO2023125787A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021143796 2021-12-31
CNPCT/CN2021/143796 2021-12-31

Publications (1)

Publication Number Publication Date
WO2023125787A1 true WO2023125787A1 (fr) 2023-07-06

Family

ID=86998165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/143330 WO2023125787A1 (fr) 2021-12-31 2022-12-29 Biomarqueurs pour le traitement du cancer colorectal

Country Status (1)

Country Link
WO (1) WO2023125787A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104822658A (zh) * 2013-06-28 2015-08-05 百济神州有限公司 作为多种激酶抑制剂的稠合三环酰胺类化合物
WO2020125762A1 (fr) * 2018-12-20 2020-06-25 Peking University Compositions et procédés de criblage génétique hautement efficace utilisant des constructions d'arn guide à code-barres

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104822658A (zh) * 2013-06-28 2015-08-05 百济神州有限公司 作为多种激酶抑制剂的稠合三环酰胺类化合物
WO2020125762A1 (fr) * 2018-12-20 2020-06-25 Peking University Compositions et procédés de criblage génétique hautement efficace utilisant des constructions d'arn guide à code-barres

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANIRUDH PRAHALLAD, CHONG SUN, SIDONG HUANG, FEDERICA DI NICOLANTONIO, RAMON SALAZAR, DAVIDE ZECCHIN, RODERICK L. BEIJERSBERGEN, AL: "Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR", NATURE, vol. 483, no. 7388, pages 100 - 103, XP055145728, ISSN: 00280836, DOI: 10.1038/nature10868 *
CORCORAN RYAN B., ANDRÉ THIERRY, ATREYA CHLOE E., SCHELLENS JAN H.M., YOSHINO TAKAYUKI, BENDELL JOHANNA C., HOLLEBECQUE ANTOINE, M: "Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer", CANCER DISCOVERY, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 8, no. 4, 1 April 2018 (2018-04-01), US , pages 428 - 443, XP093076498, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-17-1226 *
HUI,J.J. ET AL.: "Research progress of resistance mechanisms and restoring sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer", MODERN ONCOLOGY, vol. 26, no. 12, 30 June 2018 (2018-06-30), XP009547547 *
MA,R. ET AL.: "Effects of Cetuximab Combined with Vemurafenib on Colorectal Cancer Cell Lines", JOURNAL OF MICROBIOLOGY, vol. 37, no. 02, 30 April 2017 (2017-04-30), XP009547534 *
TAN,Q.H. ET AL.: "Research of BRAF-biomarker detection in colorectal cancer", CHINESE CLINICAL ONCOLOGY, vol. 16, no. 12, 31 December 2011 (2011-12-31), XP009547542 *
YAEGER RONA, CERCEK ANDREA, O'REILLY EILEEN M., REIDY DIANE L., KEMENY NANCY, WOLINSKY TAMAR, CAPANU MARINELA, GOLLUB MARC J., ROS: "Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF -Mutant Metastatic Colorectal Cancer Patients", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 21, no. 6, 15 March 2015 (2015-03-15), US, pages 1313 - 1320, XP093076499, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-14-2779 *
ZANG,L. ET AL.: "Evidence-based treatment for a patient with advanced rectal cancer with BRAF V600E mutation", TUMOR, vol. 38, no. 05, 31 May 2018 (2018-05-31), XP009547541 *

Similar Documents

Publication Publication Date Title
Lindskrog et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
US20210381062A1 (en) Nasal epithelium gene expression signature and classifier for the prediction of lung cancer
Shibuya et al. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing
Juratli et al. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome
JP2023100899A (ja) 癌の治療方法
Shukla et al. Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with EWSR1 fusion-positive sarcomas
JP7340021B2 (ja) 予測腫瘍遺伝子変異量に基づいた腫瘍分類
EP3122901B1 (fr) Fusions de gènes et variants de gènes associés au cancer
US20110189670A1 (en) Circulating Tumor and Tumor Stem Cell Detection Using Genomic Specific Probes
WO2019204576A1 (fr) Procédés et kits pour le diagnostic et le triage de patients atteints de métastases hépatiques colorectales
Jiang et al. Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment
AU2016300175A1 (en) FGFR expression and susceptibility to an FGFR inhibitor
Shen et al. A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer
IL297812A (en) Immunotherapy response signature
Durinikova et al. Targeting the DNA damage response pathways and replication stress in colorectal cancer
Braxton et al. Clinicopathogenomic analysis of mismatch repair proficient colorectal adenocarcinoma uncovers novel prognostic subgroups with differing patterns of genetic evolution
WO2023109875A1 (fr) Biomarqueurs pour le traitement du cancer colorectal
Nassar et al. Epigenomic charting and functional annotation of risk loci in renal cell carcinoma
WO2016014941A1 (fr) Procédé pour diagnostiquer un mélanome malin chez le chien domestique
WO2020092101A1 (fr) Classification de la latéralité de sous-types de consensus moléculaires
US20240112757A1 (en) Methods and systems for characterizing and treating combined hepatocellular cholangiocarcinoma
WO2023125787A1 (fr) Biomarqueurs pour le traitement du cancer colorectal
WO2023125788A1 (fr) Biomarqueurs pour le traitement du cancer colorectal
WO2023109876A1 (fr) Biomarqueurs pour le traitement du cancer colorectal
JP2024515565A (ja) ヌクレオソーム保護およびクロマチンアクセシビリティを調査するためのセルフリーｄｎａ配列データ解析法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22915037

Country of ref document: EP

Kind code of ref document: A1